A significant clinical relevance of the mode of action of IGF2BP1 for BCC treatment is that the regulation of GLI-dependent transcriptional activity by IGF2BP1 seems SMO independent [41]. The gene discussed is IGF2BP1; the disease is skin basal cell carcinoma.